Taming the beast: Interplay between gut small molecules and enteric pathogens

Aman Kumar, Melissa Ellermann, Vanessa Sperandio

Research output: Contribution to journalShort survey

Abstract

The overuse of antibiotics has led to the evolution of drug-resistant bacteria that are becoming increasingly dangerous to human health. According to the Centers for Disease Control and Prevention, antibiotic-resistant bacteria cause at least 2 million illnesses and 23,000 deaths in the United States annually. Traditionally, antibiotics are bactericidal or bacteriostatic agents that place selective pressure on bacteria, leading to the expansion of antibiotic-resistant strains. In addition, antibiotics that are effective against some pathogens can also exacerbate their pathogenesis and may lead to severe progression of the disease. Therefore, alternative strategies are needed to treat antibiotic-resistant bacterial infections. One novel approach is to target bacterial virulence to prevent or limit pathogen colonization, while also minimizing tissue damage and disease comorbidities in the host. This review focuses on the interactions between enteric pathogens and naturally occurring small molecules in the human gut as potential therapeutic targets for antivirulence strategies. Individual small molecules in the intestines modulate enteric pathogen virulence and subsequent intestinal fitness and colonization. Targeted interruption of pathogen sensing of these small molecules could therefore attenuate their virulence. This review highlights the paths of discovery for new classes of antimicrobials that could potentially mitigate the urgent problem of antibiotic resistance.

Original languageEnglish (US)
Article numbere00131-19
JournalInfection and immunity
Volume87
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Anti-Bacterial Agents
Virulence
Bacteria
Centers for Disease Control and Prevention (U.S.)
Microbial Drug Resistance
Bacterial Infections
Intestines
Disease Progression
Comorbidity
Health
Pharmaceutical Preparations
Therapeutics

Keywords

  • Clostridium difficile
  • Enteropathogens
  • Escherichia coli
  • Microbiota
  • Salmonella

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Immunology
  • Infectious Diseases

Cite this

Taming the beast : Interplay between gut small molecules and enteric pathogens. / Kumar, Aman; Ellermann, Melissa; Sperandio, Vanessa.

In: Infection and immunity, Vol. 87, No. 9, e00131-19, 01.09.2019.

Research output: Contribution to journalShort survey

@article{1fee87cbfb684e12ba4d377e3d94c685,
title = "Taming the beast: Interplay between gut small molecules and enteric pathogens",
abstract = "The overuse of antibiotics has led to the evolution of drug-resistant bacteria that are becoming increasingly dangerous to human health. According to the Centers for Disease Control and Prevention, antibiotic-resistant bacteria cause at least 2 million illnesses and 23,000 deaths in the United States annually. Traditionally, antibiotics are bactericidal or bacteriostatic agents that place selective pressure on bacteria, leading to the expansion of antibiotic-resistant strains. In addition, antibiotics that are effective against some pathogens can also exacerbate their pathogenesis and may lead to severe progression of the disease. Therefore, alternative strategies are needed to treat antibiotic-resistant bacterial infections. One novel approach is to target bacterial virulence to prevent or limit pathogen colonization, while also minimizing tissue damage and disease comorbidities in the host. This review focuses on the interactions between enteric pathogens and naturally occurring small molecules in the human gut as potential therapeutic targets for antivirulence strategies. Individual small molecules in the intestines modulate enteric pathogen virulence and subsequent intestinal fitness and colonization. Targeted interruption of pathogen sensing of these small molecules could therefore attenuate their virulence. This review highlights the paths of discovery for new classes of antimicrobials that could potentially mitigate the urgent problem of antibiotic resistance.",
keywords = "Clostridium difficile, Enteropathogens, Escherichia coli, Microbiota, Salmonella",
author = "Aman Kumar and Melissa Ellermann and Vanessa Sperandio",
year = "2019",
month = "9",
day = "1",
doi = "10.1128/IAI.00131-19",
language = "English (US)",
volume = "87",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Taming the beast

T2 - Interplay between gut small molecules and enteric pathogens

AU - Kumar, Aman

AU - Ellermann, Melissa

AU - Sperandio, Vanessa

PY - 2019/9/1

Y1 - 2019/9/1

N2 - The overuse of antibiotics has led to the evolution of drug-resistant bacteria that are becoming increasingly dangerous to human health. According to the Centers for Disease Control and Prevention, antibiotic-resistant bacteria cause at least 2 million illnesses and 23,000 deaths in the United States annually. Traditionally, antibiotics are bactericidal or bacteriostatic agents that place selective pressure on bacteria, leading to the expansion of antibiotic-resistant strains. In addition, antibiotics that are effective against some pathogens can also exacerbate their pathogenesis and may lead to severe progression of the disease. Therefore, alternative strategies are needed to treat antibiotic-resistant bacterial infections. One novel approach is to target bacterial virulence to prevent or limit pathogen colonization, while also minimizing tissue damage and disease comorbidities in the host. This review focuses on the interactions between enteric pathogens and naturally occurring small molecules in the human gut as potential therapeutic targets for antivirulence strategies. Individual small molecules in the intestines modulate enteric pathogen virulence and subsequent intestinal fitness and colonization. Targeted interruption of pathogen sensing of these small molecules could therefore attenuate their virulence. This review highlights the paths of discovery for new classes of antimicrobials that could potentially mitigate the urgent problem of antibiotic resistance.

AB - The overuse of antibiotics has led to the evolution of drug-resistant bacteria that are becoming increasingly dangerous to human health. According to the Centers for Disease Control and Prevention, antibiotic-resistant bacteria cause at least 2 million illnesses and 23,000 deaths in the United States annually. Traditionally, antibiotics are bactericidal or bacteriostatic agents that place selective pressure on bacteria, leading to the expansion of antibiotic-resistant strains. In addition, antibiotics that are effective against some pathogens can also exacerbate their pathogenesis and may lead to severe progression of the disease. Therefore, alternative strategies are needed to treat antibiotic-resistant bacterial infections. One novel approach is to target bacterial virulence to prevent or limit pathogen colonization, while also minimizing tissue damage and disease comorbidities in the host. This review focuses on the interactions between enteric pathogens and naturally occurring small molecules in the human gut as potential therapeutic targets for antivirulence strategies. Individual small molecules in the intestines modulate enteric pathogen virulence and subsequent intestinal fitness and colonization. Targeted interruption of pathogen sensing of these small molecules could therefore attenuate their virulence. This review highlights the paths of discovery for new classes of antimicrobials that could potentially mitigate the urgent problem of antibiotic resistance.

KW - Clostridium difficile

KW - Enteropathogens

KW - Escherichia coli

KW - Microbiota

KW - Salmonella

UR - http://www.scopus.com/inward/record.url?scp=85071708113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071708113&partnerID=8YFLogxK

U2 - 10.1128/IAI.00131-19

DO - 10.1128/IAI.00131-19

M3 - Short survey

C2 - 31262983

AN - SCOPUS:85071708113

VL - 87

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 9

M1 - e00131-19

ER -